ArticleTranslational cancer research2026
Loss of GGT6 promotes colorectal cancer progression and correlates with poor prognosis: a study based on multi-database mining and functional validation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gamma-glutamyl transferase 6 (GGT6) belongs to the GGT family and its functional mechanisms in colorectal cancer (CRC) are still not well understood in the academic community. This study aims to fill this research gap by examining the clinical relevance and biological effects of GGT6. Methods: GGT6 expression and clinical data were integrated from The Cancer Genome Atlas (TCGA), Human Protein Atlas (HPA), and Gene Expression Omnibus (GEO) databases. Prognostic value was assessed using Kaplan-Meier (K-M) and Cox regression. Biological pathways and immune landscapes were analyzed via Gene Set Enrichment Analysis (GSEA), CIBERSORT, and Tumor Immune Dysfunction and Exclusion (TIDE). Findings were validated using tissue microarrays and Results: GGT6 was significantly downregulated in CRC tissues, and its low expression served as an independent prognostic factor for poor survival. Functional analysis linked GGT6 to peroxisome proliferator-activated receptor (PPAR), epithelial-mesenchymal transition (EMT), and KRAS signaling. Importantly, knockdown of GGT6 significantly promoted the proliferation, migration, and invasion of HT-29 and DLD-1 cells. Furthermore, GGT6 expression correlated with immune infiltration and predicted sensitivity to common therapeutic drugs. Conclusions: GGT6 acts as a tumor suppressor in CRC. Its downregulation promotes malignant progression and correlates with poor prognosis, making it a promising biomarker and potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.